Metabolic syndrome affects the long-term survival of patients with non-endometrioid carcinoma of the uterine corpus
Metabolic syndrome affects the long-term survival of patients with non-endometrioid carcinoma of the uterine corpus
复制标题
代谢综合征影响子宫体非子宫内膜样癌患者的长期生存
DOI：
10.1002/ijgo.12984
复制
发表时间：
2019-10-15
影响因子：
3.8
通讯作者：
Ni, Juan
中科院分区：
文献类型：
--
作者：
Shou, Huafeng;Yan, Kangzhen;Ni, Juan
目的探讨代谢综合征（MS）对非子宫内膜样腺癌患者长期生存的影响。方法对2003年1月至2012年12月139例中国非子宫内膜腺癌患者进行回顾性分析。手术前接受过任何治疗的患者被排除在外。结果总体而言，41例（29.5%）患者患有多发性硬化症；MS以子宫浆液性癌发生率最高（19/45,42.2%）。对于子宫浆液性癌和腺鳞癌，MS是发病率的独立预测因素（P值分别为0.023和0.016）。在总体人群中，MS患者的生存率明显低于非MS患者（P=0.008），中位总生存期（mOS）为15个月，而MS患者为55个月（P=0.008）
Objective To probe the influence of metabolic syndrome (MS) on the long-term survival of patients with non-endometrioid adenocarcinoma. Methods Between January 2003 and December 2012, 139 Chinese patients with non-endometrial adenocarcinoma were analyzed in a retrospective study. Patients who had received any treatment before surgery were excluded. Survival times were compared between patients with and without MS. Results Overall, 41 (29.5%) patients had MS; the highest incidence of MS was observed in those with uterine serous carcinoma (19/45, 42.2%). For uterine serous carcinoma or adenosquamous carcinoma, MS was an independent predictive factor of morbidity (P=0.023 and 0.016, respectively). For the overall population, those with MS had a significantly lower survival rate than those without MS (P=0.008), and the median overall survival (mOS) was 15 months versus 55 months (P